The allure of 'ALUR'

Affiliations

¹ Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA.
² Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, USA.
³ Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, USA. Electronic address: Ignatius.ou@uci.edu.

Free article

Editorial

M Nagasaka et al. Ann Oncol. 2018.

Free article

. 2018 Jun 1;29(6):1344-1346.

doi: 10.1093/annonc/mdy144.

¹ Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, USA.
² Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, USA.
³ Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, USA. Electronic address: Ignatius.ou@uci.edu.

No abstract available

Comment on

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J. Novello S, et al. Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121. Ann Oncol. 2018. PMID: 29668860 Free PMC article. Clinical Trial.